Tandem Diabetes Care (TNDM) is expanding its product portfolio with new tubeless pump technology and next-generation closed-loop systems while driving international sales growth through direct commercialization. However, the company faces headwinds from intense competitive pressure, GLP-1 drug adoption impacts on insulin therapy demand, and supply chain constraints that are expected to persist through 2026.

Phibro Animal Health (PAHC) is gaining momentum from strong Animal Health segment growth, driven by the Zoetis MFA acquisition, vaccine expansion, and mineral nutrition demand recovery. However, the company faces headwinds from macroeconomic risks, trade policy uncertainties, and foreign exchange volatility that continue to pressure reported results.

Encompass Health Corporation (EHC) opened its first wholly owned hospital in Maine with 50 inpatient rehabilitation beds. Q2 2026 discharges rose 5.6% year-over-year, driven by new capacity and 2.8% same-store growth. EHC opened three hospitals in the first half of 2026 and plans to open eight new hospitals throughout the year, reflecting its strategy to expand capacity in favorable markets.

Thermo Fisher Scientific (TMO) is strengthening growth through innovation, AI investments, and strategic acquisitions expected to contribute $1.6 billion in revenues and 32 cents to adjusted EPS in 2026. The company expects organic revenue growth at 3%-4% for 2026 supported by broad-based end-market improvements. However, risks from macroeconomic uncertainty, inflation, geopolitical disruption, and unfavorable currency movements could weigh on results and margins.

Neogen (NEOG) shares have surged 83% year-to-date, outperforming the S&P 500, driven by strong Food Safety segment growth with core revenue increases of 5.8% in Q4 fiscal 2026. The company is expanding manufacturing capabilities following its 3M Food Safety acquisition, planning a 50% increase in R&D spending for fiscal 2027 focused on pathogen detection and sanitation platforms. However, fiscal 2027 EPS is projected to decline 3.1% before recovering with 17.2% growth in fiscal 2028.

Integra LifeSciences (IART) reported 1.6% organic growth in Specialty Surgery revenues driven by neurosurgery strength and improved supply reliability. Adjusted EPS rose 24.4% with margin expansion, and the company is ramping up Braintree production for a SurgiMend relaunch. However, elevated leverage at 4.1X and foreign exchange headwinds pressured full-year revenue guidance and financial flexibility.

Chewy's Vet Care portfolio achieved triple-digit revenue growth in Q2, demonstrating strong customer satisfaction, veterinarian retention, and compelling clinic economics. The company expects its Health segment, including Modern Animal, to deepen customer engagement and expand wallet share as it scales. However, Chewy carries a Zacks Rank #4 (Sell) rating and has underperformed its industry by 44.7% over the past six months.

Labcorp Holdings is expanding its specialty testing business in oncology, women's health, autoimmune disease, and neurology through strategic acquisitions and partnerships. The company is leveraging AI and automation to improve margins, with operating margins expanding 70 basis points year-over-year. However, macroeconomic uncertainty, cost inflation, and changing reimbursement policies pose risks to testing volumes and profitability.

In a comparison of two Medical-Products sector stocks, Phibro Animal Health (PAHC) emerges as the better value opportunity compared to Haemonetics (HAE). PAHC holds a Zacks Rank #2 (Buy) with a Value grade of A, featuring a forward P/E of 10.06 and PEG ratio of 1.02. HAE has a Zacks Rank #3 (Hold) with a Value grade of C, showing a forward P/E of 20.36 and PEG ratio of 2.15, making PAHC more attractive to value investors.

Zacks.com highlighted four stocks with strong interest coverage ratios as a screening strategy for investors navigating elevated Treasury yields and higher borrowing costs. The featured companies—DiamondRock Hospitality, Vertiv Holdings, Mueller Water Products, and Phibro Animal Health—all carry Zacks Rank #2 ratings and demonstrate solid earnings surprises and growth potential, making them better positioned to absorb higher financing costs.

In a comparison of two Medical-Products sector stocks, Phibro Animal Health (PAHC) emerges as the superior value investment option compared to LeMaitre Vascular (LMAT). PAHC holds a Zacks Rank of #2 (Buy) with a Value grade of A, featuring a forward P/E of 11.20 and PEG ratio of 1.13. LMAT, rated #4 (Sell) with a Value grade of D, has a forward P/E of 28.10 and PEG ratio of 2.34, indicating it is relatively overvalued.

Phibro Animal Health (PAHC) reported Q2 2026 total revenue of $396.7 million, up 4.8% year-over-year. International markets contributed significantly, with Latin America and Canada delivering a notable 26.37% revenue surprise at $90.22 million. The company holds a Zacks Rank #3 (Hold) rating, with analysts projecting full-year revenue of $1.57 billion, up 3.7% annually. Stock performance has lagged the broader market over the past month but outperformed over three months.